dopamine d2‐like receptors

Eticlopride, an antipsychotic, is a Selective dopamine D2/D3 receptor antagonist (Ki: 0.5/0.16 nM).

ONC206, an analogue of the TRAIL inducer ONC201, acts as a selective antagonist of the D2-like dopamine receptors (DRD2/3/4) at nanomolar concentrations and possesses broad-spectrum anti-tumor activity.

Cabergoline (FCE-21336) is an ergot derived-dopamine D2-like receptor agonist. It has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).Cabergoline permits rapid and effective hormonal and tumor control by normalizing prolactin-producing pituitary adenomas levels.

ECPLA is an LSD analog and a potent 5-HT2A agonist (EC50 of 14.6 nM), capable of stimulating Gq-mediated calcium flux. It exhibits high affinity for most serotonin receptors, α2-adrenergic receptors, and D2-like dopamine receptors.

N-Methylspiroperidol is a D2 receptor antagonist. This compound can be labeled as [18F]N-Methylspiroperidol, which allows for the investigation of its interaction with 5-HT2C receptors via PET (positron emission tomography), as well as examining the competition and impact of neurotransmitters like dopamine on these receptors.

MeSeI exhibits weak inhibitory activity against monoamine oxidases MAO-A and MAO-B, with IC50 values of 198.8 µM. It modulates dopamine receptor D2 (dopamine receptorD2) and norepinephrine receptors α2, β1 (norepinephrine receptor α2, β1), displaying antidepressant-like effects in mice. Additionally, MeSeI is orally active.